Thalassemia intermedia is a genetically diverse group of diseases that is the result of an imbalance in the production of the alpha and beta chains with ensuing chronic hemolysis, ineffective erythropoiesis, and iron overload.Resulting complications include bone changes, hypercoagulability, and end-organ damage due to iron overload. This decade has witnessed major breakthroughs in the management of thalassemia. In this article, we examine these novelties in therapy including iron chelation therapy, stem cell transplant, and gene therapy.Iron chelation therapy has been revolutionized with the advent of deferasirox, a once-daily oral iron chelator, that has been shown to be safe and efficacious.Gene therapy was also at the core of this revolution with the discovery of novel gene elements and viral vectors allowing for better control and improved outcomes.
Pathophysiology
Beta-thalassemia is an inherited genetic hemoglobin disorder characterized by decreased synthesis of the beta globulin of hemoglobin. The alpha and betachains in a normal red blood cell (RBC) should be in stoichiometric proportion. Underproduction of the beta chains in beta-thalassemia causes excess unstable alpha chains to deposit in the RBC.This increases the oxidative damage to the membrane andcauses subsequent lysis of the cells.The premature death of the RBCs by this process is called ineffective erythropoiesis (1) .The bone marrow will react to compensate for the anemia resulting in characteristic deformities of the skull and face because of hypertrophy.Cortical thinning and pathological fractures are also common (2, 3) . The primary determinant of the anemia is the degree of ineffective erythropoiesis rather than the degree of hemolysis, which only plays a secondary role (4) .Hemolysis is linked to the hypercoagulable state in TI (5) leading to silent infarcts (6) and pulmonary hypertension. The anemia and the ineffective erythropoiesis will increase intestinal iron absorption leading to iron overload, which causes heart failure, endocrine abnormalities and others. Thus, ineffective erythropoiesis, chronic hemolysis, and iron overload are the factors behind all the complications of TI.
As the medical care we provide for thalassemia patients improves, the life span of the patients is also increasing. This gives us a chance to witness more and more complications. We have shown that TI patients are at a higher risk of thrombosis than TM patients. Out of 2190 TI patients, 3.9% experienced a thrombotic event compared to only 0.9% of 6,670 TM patients (7) . The events were mainly venous and were divided into deep vein thrombosis (40%), portal vein thrombosis (19%), stroke (9%), pulmonary embolism (12%), and others (20%). What's more striking is that splenectomised patients were found to be at a higher risk of thrombosis than non-splenectomised patients. Patients with low hemoglobin concentration (<9 g/dl) and non-transfused patients were also found to be at higher risk of thrombosis. Studies are still lacking in this subject but there are several proposed mechanisms. RBC remnants express negatively charged phosphatidylserine residues on their membranes which act as procoagulants, initiating thrombosis (8, 9) . Activation of platelets, endothelial cells, monocytes, and depletion of antithrombotic factors are also incriminated along with the cardiac, endocrine, and hepatic dysfunction (10) . Other risk factors also include age (11), previous thromboembolic events, and family history.It is important to recognize these risks in our patients and treat accordingly since if left untreated, the recurrent thromboembolic phenomena can lead to pulmonary hypertension with ensuing secondary heart failure (12) ,in addition to silent brain abnormalities (6, 13) . Recommended therapies include aspirin or other platelet anti-aggregants in the case of thrombocytosis, or anticoagulant agents such as low molecular weight heparin in patients with documented thrombosis or for those undergoing surgery. Blood transfusions might be considered as they dilute the circulating damaged RBCs. More studies are needed to establish a risk-assessment model that would stratify the patients according to their risks and guide a tailored therapy to this issue.
Pietrangelo (14) compared the process of iron regulation to that of glucose regulation. Even though our precise knowledge of the elements involved in iron regulation is still quite lacking, this simile holds in many aspects, with hepcidin being the counterpart of insulin. Iron is controlled by a negative feedback loop. Inflammation and excess plasma iron, just like excess glucose, is a stimulant for the transcription of hepcidin. Hepcidin interacts with ferroportin -the iron exporter -on the basolateral surfaces of hepatocytes and the intestinal epithelium and causes its internalization and degradation (15) . This traps iron inside the cells and makes it less available in the blood stream. In the hepatocytes, macrophages, and other cells of the reticuloendothelial system, it is stored in its ferritin-bound form for later use, just like glycogen. In the endothelial cells, intracellular iron is shed with the shedding of the epithelium. Hypoxia, anemia, and a demand for erythropoiesis suppress hepcidin, making more iron avail- able for the bone marrow through increased intestinal absorption and better recycling of catabolic iron from the reticuloendothelial system (16) . In fact, the ineffective erythropoiesis is an unrelenting signal to downregulate hepcidin by increasing expression of growth differentiation factor 15 (GDF15) and hypoxia-inducible transcription factors (HIFs) (16) , thus dumping more iron in the plasma through increasing intestinal absorption and depleting the macrophages of their iron stores. After all the iron saturates the transferrin stores, it is transported as the toxic non-transferrin-bound-iron. The end result is deposition in the parenchyma of the liver, heart, endocrine organs, and others. Coming back to the analogy, thalassemia intermedia is a lot like diabetes mellitus type 2. Hormonal failure, manifesting either as decreased secretion or as decreased sensitivity, is the culprit in both.
Body iron levels are usually assessed by ferritin values. However, studies have shown that ferritin underestimates the total iron burden in TI, or at least does not increase as much as TM (17) . For the same value of LIC, ferritin values in TI patients were significantly lower than TM patients. A proposed mechanism for this is that iron in transfused patients is preferentially distributed to the reticuloendothelial system, thus ferritin is more readily synthesized and exported (16) . This is in contrast to transfusion-independent TI patients, where the low hepcidin depletes the reticuloendothelial system of its iron stores, thus ferritin will be low.Other methods of evaluating body iron stores include determination of liver iron concentration by biopsy or more recently by non-invasive techniques such as R2 MRI.
The main indications for splenectomy in TI are poor growth and development, increased transfusion demand, hypersplenism, and splenomegaly (18) . However, splenectomy appears to contribute to an increased risk of thrombosis (9, 19) . Splenectomy is now less common than before and is performed later in life (20) . Gallstones are common in TI because of the ineffective erythropoiesis and peripheral hemolysis. That is why the gallbladder should be inspected during splenectomy to avoid further complications.
Extramedullary hematopoiesis (EMH) is when erythropoietic tissue outside the confines of marrow spaces in bones increase to compensate for the chronic state of anemia that accompanies TI. This will lead to the formation of erythropoietic masses that will primarily affect the spleen, liver, and lymph nodes (20) . These masses can cause local symptoms such as neurological symptoms and spinal cord compressions (21, 22) . There is even one case report on hematopoietic masses causing recurrent pleural effusion (23) . Splenic enlargement can cause symptoms such as early satiety, left upper quadrant pain, and even raises concerns about splenic rupture (18) . Extramedullary hematopoiesis is routinely managed by radiotherapy, hydroxyurea, or transfusion therapy (21, 24, 25) .
Pulmonary hypertension (PH) is defined as pulmonary artery pressure of >25 mm Hg at rest or >30 mm Hg during exercise (26) . PH is quite prevalent in hemolytic anemias in general and in TI, the prevalence is estimated to be around 59%.This, in turn, contributes to an increased incidence of congestive heart failure (27) .The etiology of PH in TI is multifactorial, and its pathogenesis is complicated, but as we gain more insight into this disease, we are better able to treat it and even prevent it. PH results from interplay of vasoconstriction, vascular smooth muscle proliferation, and dysfunctional endothelium with resulting thrombosis, all of which contribute to luminal narrowing and right-sided failure. Major risk factors include advancing age and a history of splenectomy (28) . Autopsy studies in thalassemic patients have revealed common histopathological findings that include plexiform and concentric medial hyperplastic pulmonary vascular lesions, and in situpulmonary artery thrombosis (29, 30) . The factors that culminate in these pathologies are most likely the result of the long-term sequelae of splenectomy, red cell membrane pathology, coagulation abnormalities, excess arginase activity, low nitric oxide bioavailability, platelet activation, oxidative stress, iron overload, and chronic hemolysis (31-
and serum ferritin (37) .Hemolysis disables the arginine-nitric oxide pathway by releasing erythrocyte arginase (38) and cell-free hemoglobin (33) . With the consumption of nitric oxide and arginine, endothelial dysfunction ensues, and along with the intravascular hemolysis, this will create a procoagulant state (39) . Iron overload, and the subsequent oxidative stress, can also contribute to increasing the pulmonary vasculature resistance through various mechanisms. They induce pulmonary fibrosis and affect the pump itself through cardiac siderosis (40) . The hypoxemia, along with the chronic anemia, will also exacerbate the vasoconstriction (28) .
Currently, there are no guidelines for the treatment of PH in TI specifically. In one small trial, PH was absent in patients taking hydroxyurea suggesting a protective role, but further studies are needed (41) . Two small studies reported improvement in exercise tolerance in response to sildenafil (42, 43) . General recommendations for the management of PH now are adequate treatment of thalassemia, any precipitating factors or associated diseases, in addition to supportive measures (28) . A multidisciplinary approach is needed and a cardiopulmonary specialist should be on board.
TI patients are also at risk for other complications. Leg ulcers occur more commonly in older patients. Leg ulcers develop in some patients with low hemoglobin and do not develop in others, even though they are maintained at the same amount of fetal hemoglobin, implying that it is definitely an interplay of several factors. The skin might be at a lower oxygen tension due to the anemia, making it fragile and more prone to break upon minimal trauma. The healing process would also be impaired under these conditions. These are usually managed by an intense transfusion regimen to elevate the hemoglobin concentration by a minimum of 2 g/dl. Other possible interventions include elevating the end of the bed so as to keep the lower limbs at a level above the heart. This provides better venous return and increases the perfusion pressure of the affected area (20) . Zinc supplementation (44), pentoxifylline, and hydroxyurea, without or without erythropoietin (45) are also possible options.
While endocrine dysfunction can be quite common in TM, it is quite rare in TI. Patients generally experience late puberty, but their sexual development is normal and their fertility preserved. However, hypothyroidism can be a late occurrence sometimes (20) .
Viral hepatitis is much rarer in TI than in TM due to the fact that TI patients are less often transfused. Nevertheless, the risk is not absent and careful monitoring should be undertaken. With the advent of better medical care and chelation therapy, TI patients are surviving longer and new complications such as hepatocellular carcinoma are emerging ( Figure 1, Table 1 ) (46) .
Management
The management of TI has truly come a long way this decade especially the breakthroughs in oral iron chelation therapy, gene therapy, and the promised breakthroughs in JAK2 inhibitors. Transfusion is definitely the only available salvage therapy when severe symptoms of anemia set in, including developmental delay in the pediatric age group. Associated risks include alloimmunisation, which is relatively common in TI, especially if transfusions are instituted after the age of 12 months (47) . Rhesus and Kellphenotyping is recommended prior to transfusion (48) , with some physicians advocating a short course of steroids for 3 -5 days concomitantly, even though this remains controversial.
Iron chelation therapy is the mainstay of treatment of TI and studies demonstrating the efficacy and benefits of this study are increasing by the day. The rate of iron loading in TI is variable and changes with transfusional load. Iron loading in non-transfused patients is estimated to be 2 -5 grams per year (49) compared to 7.5 -15.1 grams per year for transfused patients (50) .Iron loading should always be assessed by liver iron concentration (LIC), preferably by non-invasive MRI imaging, and iron chelation therapy initiated accordingly. Previously, an LIC of 7 mg Fe/g dry weight was used to initiate therapy; however, a recent study has found that an LIC of 7 mg Fe/g dry weight is associated with vascular complications and an LIC of 6 mg Fe/g dry weight is associated with endocrine comorbidities, meaning that complications would have already set in, and chelation should start before that (51) . The gold standard remains desferrioxamine injections which is given subcutaneously or intravenously for prolonged periods of time and is associated with significant patient discomfort, decreased quality of life, and non-compliance (52, 53) despite significant mortality and morbidity reductions (54) . Deferasirox, a once-daily oral iron chelator, has been found to be safe and efficacious over a wide range of transfusion-dependent anemias and heavily iron-loaded patients (55, 56) . A pilot study has also shown it to be effective in reducing iron burden in TI patients (57) . A large randomized, double-blind, placebo-controlled study is ongoing to determine the efficacy and safety of deferasirox in TI and other non-transfusion-dependent anemias.
A novel oral iron chelator is also under development for clinical use. The molecule is still in phase I clinical trials, but the results seems promising (58) . The authors state that extensive preclinical Extensive preclinical toxicological studies demonstrated a higher no-observableadverse-effect level (NOAEL) compared to deferasirox.
Hematopoietic stem-cell transplantation is essentially curative in properly selected candidates. Good candidates with high success rates include pediatric patients who have not developed complications such as viral hepatitis or severe iron overload and who receive HLA-identical related donor stem-cell transplants. The event-free survival for beta-thalassemia patients reported from several groups is 80-90 % with less than 10% mortality and minimal morbidity, apart from impaired fertility (59) (60) (61) (62) .The problem is in the availability of donors. Disease-free survival is lower, and morbidity and mortality is higher with unrelated haploidentical donors (63) (64) (65) . Definitive hematopoietic stem cells can be obtained from cord blood. Several studies have assessed the use of cord-blood transplantation for patients with thalassemia (61) , and the outcomes of related cord-blood stem cell transplantation for beta-thalassemia are approaching those of conventional bone marrow transplantation with disease-free survival of 90%. A cord-blood bank will also allow unrelated transplants to take place, but data is still scarce (66) (67) (68) . A recent review cited a personal communication from a member of the Eurocord cooperative group that this is feasible, albeit less successful than HLA-compatible cord-blood transplant from a sibling (69) . The physician, patient, and everybody concerned should be involved in the transplantation decision given the associated morbidity, mortality, and cost of the procedure. Thalassemia is an ideal disease for gene therapy since its genetic defect only affects the erythroid lineage in the hematopoietic system. The concept it is simple, albeit the mechanism is technically demanding. Hematopoietic stem cells are harvested from the patient and infected with a virus carrying the beta-globin gene along with its upstream regulatory elements, and then infused back after myelosuppression. The fact that the patient's own cells are used overcomes the problem of scarcity of donors and associated immunological complications.
This field has also witnessed a great deal of progress lately and many obstacles have been reduced. A lot of work has been put to develop viral constructs that are able to accommodate all the sequences needed for the expression of the beta-globin gene. The position where the construct integrates also has grave effects. Therefore, boundary elements are now frequently included in the genetic complexes. Boundary elements are sequences that flank the gene and delimit the activity of the regulatory elements of that gene (70) . Another setback was the associated risk of leukemia with the use of retroviral vectors. Therefore, lentiviral vectors were developed and they have proven successful in mouse models both in TM and TI (71) (72) (73) (74) (75) (76) . A clinical trial to test this lentiviral vector has already begun in 2007 on two patients (77, 78) . One of the patients needed rescue with non-manipulated cells while the other achieved 10% engraftment and was able to become transfusion independent. The future of gene therapy probably lies in induced pluripotent stem cells, which are human somatic cells that are reprogrammed to form multipotent stem cells (79, 80) .
Ineffective erythropoiesis is when erythroid progenitor cells fail to mature, die in the process, or develop into abnormal erythrocytes that eventually die prematurely. This process is due to chain imbalances in the erythroid precursors and is the root of the pathophysiology in thalassemia. The premature erythrocytes produced undergo premature apoptosis, leading to intravascular and medullary hemolysis. Ineffective erythropoiesis also causes a compensatory expansion of the erythron, even though it still fails to maintain a normal numbers of erythrocytes. This will produce characteristic deformities of the skull and spine, osteoporosis, and bone demineralization. The spleen will also enlarge, thus exacerbating the anemia by sequestration of red blood cells. Ineffective erythropoiesis will also downregulate hepcidin, thus instituting a state of iron overload. Data showed that in ineffective erythropoiesis, there is an accumulation of proliferating erythroid progenitors, and there was an increase in the percentage of erythroid cells in the S-phase. The thalassemic cells were associated with the expression of certain cell-cycle regulatory genes such as EpoR, Jak2, cyclin-A, Cdk2, Ki-67 and the antiapoptotic protein Bcl-XL, and differentiated less. In thalassemic mice, a Jak2 inhibitor reversed ineffective erythropoiesis and decreased spleen size with limited effect on anemia. Jak2 inhibitors would be expected to limit or reduce splenomegaly, thus improving anemia and delaying the need for splenectomy -a procedure which carries its own complications. A decrease in ineffective erythropoiesis is also expected to upregulate hepcidin, thus improving the metabolism of total body iron content and decreasing endorgan damage (81) (82) (83) . 
